Zelira Therapeutics
  • HOME
  • ABOUT
    • OUR COMPANY
    • BOARD
    • ADVISORY BOARD
    • LOCATIONS
    • MEDICAL CANNABIS
      • SCIENCE
      • LEGALISED MARKETS
  • RESEARCH
    • PRODUCT PIPELINE
    • PRECLINICAL
      • PANCREATIC CANCER
      • BREAST CANCER
      • BRAIN CANCER
      • DIABETES RELATED COGNITIVE DECLINE
    • CLINICAL TRIALS
      • AUTISM
      • INSOMNIA
      • CHRONIC PAIN
  • PRODUCTS
    • Doctors
    • Pharmacists
    • Patients
  • INVESTORS
    • ASX ANNOUNCEMENTS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • PRESENTATIONS & VIDEOS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • REPORTS
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
  • MEDIA
    • VIDEOS & AUDIOS
    • ARTICLES
    • Autism Symposium
  • CONTACT
  • HOME
  • ABOUT
    •         - OUR COMPANY
    •         - BOARD
    •         - ADVISORY BOARD
    •         - LOCATIONS
    •         - MEDICAL CANNABIS
      •                 - SCIENCE
      •                 - LEGALISED MARKETS
  • RESEARCH
    •         - PRODUCT PIPELINE
    •         - PRECLINICAL
      •                 - PANCREATIC CANCER
      •                 - BREAST CANCER
      •                 - BRAIN CANCER
      •                 - DIABETES RELATED COGNITIVE DECLINE
    •         - CLINICAL TRIALS
      •                 - AUTISM
      •                 - INSOMNIA
      •                 - CHRONIC PAIN
  • PRODUCTS
    •         - Doctors
    •         - Pharmacists
    •         - Patients
  • INVESTORS
    •         - ASX ANNOUNCEMENTS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
    •         - PRESENTATIONS & VIDEOS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
      •                 - 2015
    •         - REPORTS
    •         - STOCK INFORMATION
    •         - CORPORATE GOVERNANCE
  • MEDIA
    •         - VIDEOS & AUDIOS
    •         - ARTICLES
    •         - Autism Symposium
  • CONTACT

Category Archives: articles-2018

Prescription Opioid Crisis

By Zelira TherapeuticsNovember 27, 2018articles-2018

Prescription Opioid Crisis

Read More

ASX Announcement: Zelda Partners St Vincent’s Hospital on Opioid Reduction Study

By Zelira TherapeuticsNovember 26, 2018articles-2018

ASX Announcement: Zelda Partners St Vincent’s Hospital on Opioid Reduction Study

Read More

VIRIATHUS RESEARCH REPORT

By Zelira TherapeuticsSeptember 13, 2018articles-2018

VIRIATHUS RESEARCH REPORT View full report

Read More

Viriathus Research Report

By Zelira TherapeuticsSeptember 13, 2018articles-2018

Viriathus Research Report

Read More

PAEDIATRIC BRAIN CANCER RESEARCH UPDATE

By Zelira TherapeuticsJune 6, 2018articles-2018

PAEDIATRIC BRAIN CANCER RESEARCH UPDATE

Read More

‘Medicinal cannabis: Australia isn’t as progressive as it may seem” – By Dr. Stewart Washer

By Zelira TherapeuticsFebruary 20, 2018articles-2018

‘Medicinal cannabis: Australia isn’t as progressive as it may seem” – By Dr. Stewart Washer

Read More

ASX Announcement: Shares Begin Trading in the USA on the OTCQB Venture Market

By Zelira TherapeuticsJanuary 22, 2018articles-2018

ASX Announcement: Shares Begin Trading in the USA on the OTCQB Venture Market

Read More

SUBSCRIBE

Zelira TherapeuticsFollow

Zelira Therapeutics
30 Jul

Zelira has released its most recent quarterly report for the 2021 financial year.

The Q4 highlights include strong growth on Q3 cash receipts (+38%), accelerating commercialisation and the achievement of significant research milestones.

Read more here:
http://ow.ly/xleR50FGLmK

Twitter 1420955741767208960
Load More...

CONTACT US

    Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.